CellCept, Mycophenolate

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 34 in CellCept, Mycophenolate (generic)

  1. Aurinia To Host Lupus Opinion Leader Meeting And Webcast On October 23 In New York CityRead the original story

    6 hrs ago | BioSpace

    Aurinia Pharmaceuticals Inc. today announced that it will host a Lupus Key Opinion Leader breakfast on Thursday, October 23, 2014 from 8am-9:30am Eastern Time in New York City. The meeting will feature Mary Anne Dooley, M.D. MPH, an internationally renowned expert and a pioneering leader in many national and international lupus initiatives, including the Systemic Lupus International Collaborating Clinics and the Lupus Clinical Trials Consortium.


  2. Blood test helps predict relapse in patients with autoimmune disease affecting the kidneysRead the original story w/Photo

    Thursday Oct 16 | Science Daily

    Among patients with an autoimmune disease called ANCA-associated vasculitis, autoantibody increases were linked with an 11-fold increased risk of relapse in patients whose kidneys were affected, a study concludes. Among patients without kidney involvement, such increases were associated only weakly with relapses.


  3. Sjogren s syndrome and Neuromyelitis Optica spectrum...Read the original story

    Wednesday Oct 8 | BioMed Central

    BackgroundNeuromyelitis optica is a rare relapsing auto-immune disease of the central nervous system which is sometimes found in association with other autoimmune disorders including Sjogren's syndrome. We present the case of a middle aged female with Sjogren's syndrome and Neuromyelitis optica spectrum disorders who had a rapidly declining neurological illness that responded to immunosuppressive therapy.Case presentationA 51-year-old female with Sjogren's syndrome and recent history of varicella zoster infection presented with right upper and lower extremity weakness of one week duration.


  4. Extracorporeal photopheresis for treatment of adults and children...Read the original story

    Tuesday Oct 7 | Bone Marrow Transplantation

    Correspondence: Dr E Das-Gupta, Centre for Clinical Haematology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK. E-mail: Emma.das-gupta@nhs.net Extracorporeal photopheresis has been used for over 20 years to treat acute GVHD and chronic GVHD.


  5. Interleukin-2-stimulated natural killer cells are less susceptible to ...Read the original story

    Tuesday Sep 23 | CiteULike

    Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. In a clinical phase I/II trial, pediatric patients with high-risk malignancies were treated with ex vivo IL-2-stimulated donor natural killer cells after transplantation with haploidentical stem cells.


  6. ''Feeble' Health Canada can't block dodgy drug importsRead the original story w/Photo

    Sep 19, 2014 | The Toronto Star

    Canadian drug regulator Health Canada failed to stop pharmaceutical giant Apotex from importing suspect drug ingredients from one of its troubled manufacturing plants in India. Instead, the potentially unsafe products were allowed into the country to be used in the making of generic blood pressure medications, antihistamines and other drugs for Canadian consumption.


  7. Multimodality Imaging of Hypertrophic Cardiomyopathy in a...Read the original story

    Sep 15, 2014 | Circulation

    From the Noninvasive Cardiovascular Imaging Section, Cardiovascular Division, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA ; and Division of Cardiovascular Medicine, Center for Advanced Heart Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA . Correspondence to Marcelo F. Di Carli, MD, Brigham and Women's Hospital, Nuclear Medicine/Radiology, 75 Francis St, Boston, MA 02115.


  8. Guest Post: Nine Mandatory Licences Allow Greater Access To Medicines In EcuadorRead the original story

    Sep 12, 2014 | Intellectual Property Watch

    What is a mandatory licence? Mandatory licences are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country. Ketty Veliz, patent coordinator of the Ecuadorian Institute of Intellectual Property , said that "with the patent we give a monopoly for 20 years and when an invention has a patent, prices are high.


  9. Researchers from Pharmacology Research Laboratories Report Findings...Read the original story

    Sep 10, 2014 | Hispanic Business

    In this study, the efficacy of a novel fully human anti-CD40 monoclonal antibody-ASKP1240, administered as a monotherapy or combination therapy , on the prevention of renal allograft rejection was evaluated in Cynomolgus monkeys." Our news journalists obtained a quote from the research from , "Heterotopic kidney transplants were performed in ABO-compatible, stimulation index 2.5 or higher in the two-way mixed lymphocyte reaction monkey pairs.


  10. Study examines immunosuppressant effect on central nervous system disorderRead the original story w/Photo

    Sep 9, 2014 | Medical News Today

    In patients with neuromyelitis optica spectrum disorder , the immunosuppressant medication mycophenolate mofetil appears to reduce the frequency of relapse, stabilize or improve disabilities and be well tolerated by patients. Disabilities from NMOSD arise due to acute attacks and just one or two attacks can lead to blindness or a walking disability.


  11. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.Read the original story

    Aug 11, 2014 | CiteULike

    Hepatitis C virus infection affects around 3% of the world population or approximately 160 million people.


  12. Kidney recipient finds endless headaches in obtaining needed pillsRead the original story

    Jul 25, 2014 | Daily Herald

    Having once offered my close friend Irene a kidney, I am always relieved to find her looking good and healthy when we meet.


  13. Immunosuppressive treatments in multiple sclerosis.Read the original story

    Jul 11, 2014 | CiteULike

    Multiple sclerosis is a heterogeneous autoimmune disorder of the central nervous system that is enigmatic, relapsing, and in some instances progressive.


  14. Transplant Champ Goes Nuts Begging for Pills: HoelterhoffRead the original story

    Jul 8, 2014 | Bloomberg

    Having once offered my close friend Irene a kidney, I am always relieved to find her looking good and healthy when we meet.


  15. Severe Forms of Ocular Surface DiseaseRead the original story w/Photo

    Jul 3, 2014 | Contact Lens Spectrum

    One of the most commonly observed forms of ocular surface disease affecting the ocular surface ecosystem is keratoconjunctivitis sicca - either aqueous-deficient or evaporative forms.


  16. Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus NephritisRead the original story

    Jun 26, 2014 | Drugs.com

    June 26, 2014- Aurinia Pharmaceuticals, Inc., today announced enrollment of the first patient in its planned Phase 2b clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis .


  17. New guidance on how and when to stop immunosuppressants in lupus patientsRead the original story

    Jun 11, 2014 | PhysOrg Weblog

    A new study presented today at the European League Against Rheumatism Annual Congress showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease.1 Within two years, it was possible to stop the immunosuppressant in about 70% of ... (more)


  18. Veloxis Pharmaceuticals A/S Announces Senior Level Appointments In...Read the original story

    Jun 4, 2014 | BioSpace

    Veloxis Pharmaceuticals A/S Announces Senior Level Appointments In Preparation For U.S. Commercialization Of Envarsus XR /PRNewswire/ -- Veloxis Pharmaceuticals A/S today announced the hiring of senior level management in preparation for potential U.S. commercialization of EnvarsusA XR EnvarsusXR is an extended release formulation of tacrolimus ... (more)


  19. Time-dependent variability in tacrolimus trough blood levels is a...Read the original story

    May 30, 2014 | Kidney International

    Correspondence: S. Joseph Kim, Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, 585 University Avenue, 11C-1183, Toronto, Ontario, Canada M5G 2N2.


  20. Veloxis Announces Senior Level Appointments in Preparation for U.S....Read the original story

    Jun 3, 2014 | GlobeNewswire

    Veloxis Pharmaceuticals A/S today announced the hiring of senior level management in preparation for potential U.S. commercialization of EnvarsusA XR an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients.